Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

Study Overview
=================
Brief Summary
-----------------
The study proceeds with prospective, randomized, open and controlled clinical trials. The subject of the investigator's study was the first patient diagnosed with dilated cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet the selection / exclusion criteria were randomly assigned to each group, and the experimental group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.

Detailed Description
-----------------
Myocardial viability plays an important role in improving the function of the heart. To date, the most reproducible and objective method has been established as a method or tool for assessing myocardial viability. Olmesartan is known to have the strongest inhibitory ability of angiotensin receptors compared with other angiotensin receptor binding inhibitors. Research has been reported that statin drugs may help improve vascular endothelial function, and several researchers have suggested that these mechanisms may affect the improvement of myocardial survival. In addition, studies have shown that angiotensin receptor binding inhibitors and statins may improve left ventricular function in patients with left ventricular function. However, since the studies did not assess myocardial survival, the mechanisms could not be clearly identified. The purpose of this study is to investigate the effect of olmesartan on myocardial survival in patients with dilated cardiomyopathy who have left ventricular dysfunction.

Official Title
-----------------
Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

Conditions
-----------------
Dilated Cardiomyopathy

Intervention / Treatment
-----------------
* Diagnostic Test: FDG PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: dilated cardiomyopathy Exclusion Criteria: contraindication to angiotensin receptor blocker cardiogenic shock sensitive to rosuvastatin liver cirrhosis more than Child class B

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Olmesartan group<br>olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month | Diagnostic Test: FDG PET<br>* baseline and 6-month follow-up FDG PET<br>|
| Active Comparator: Valsartan group<br>valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month | Diagnostic Test: FDG PET<br>* baseline and 6-month follow-up FDG PET<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of glucose metabolism | data from fludeoxyglucose positron emission tomography | 6 month |